Admune Therapeutics

Danvers, United States Founded: 2013 • Age: 13 yrs Acquired By Novartis
Cytokine therapy drugs are developed for metastatic cancer treatment.

About Admune Therapeutics

Admune Therapeutics is a Healthcare company based in Danvers (United States) founded in 2013, and was acquired by Novartis in October 2015. Cytokine therapy drugs are developed for metastatic cancer treatment. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.

Company details

Admune Therapeutics, affiliated with Marine Polymer Technologies is a clinical-stage biotech company that develops cytokine therapy drugs for the treatment of metastatic cancers including melanoma, renal cell carcinoma, non-small cell lung cancers (NSCLC) and others. It has proprietary technologies for the production and use of heterodimeric IL-15Ra (hetIL-15) in cancer immunotherapy. The program is currently in phase 1 clinical trial through the National Cancer Institute at the National Institutes of Health. Admune was acquired by Novartis on Oct 21, 2015 and is currently operating as its subsidiary.

  • Headquarters Danvers, United States
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website admune.com
  • Acquired by Novartis (Oct 2015)
Key Metrics

Investors in Admune Therapeutics

Admune Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Novartis.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
R&D focused on manufacturing of drugs for multiple therapeutic areas
1996novartis.comBasel, Switzerland
Premium access

Investor details for Admune Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Admune Therapeutics

2 dated milestones of Admune Therapeutics across 2 years, from founding to its latest funding, stage changes and deals.

  1. Founded Admune Therapeutics is founded.
  2. Exit Acquired by Novartis.

Competitors of Admune Therapeutics

Admune Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
c4therapeutics.com2016Cambridge, United States$223M121
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
erasca.com2018San Diego, United States$300M120
Small molecule therapeutics for cancer treatment are developed.
miragen.com2007Boulder, United States$111.29M92
MicroRNA-based therapeutics are developed for treating multiple diseases.
Premium access

Detailed competitors of Admune Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as Admune Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Admune Therapeutics

Admune Therapeutics was founded in 2013.

Admune Therapeutics is headquartered in Danvers, United States. It is registered at Danvers, Massachusetts, United States.

Admune Therapeutics, affiliated with Marine Polymer Technologies is a clinical-stage biotech company that develops cytokine therapy drugs for the treatment of metastatic cancers including melanoma, renal cell carcinoma, non-small cell lung cancers (NSCLC) and others. It has proprietary technologies for the production and use of heterodimeric IL-15Ra (hetIL-15) in cancer immunotherapy. The program is currently in phase 1 clinical trial through the National Cancer Institute at the National Institutes of Health. Admune was acquired by Novartis on Oct 21, 2015 and is currently operating as its subsidiary.

Admune Therapeutics's top competitors include C4 Therapeutics, Erasca and MiRagen.

Admune Therapeutics has 1 investor. Key investors include Novartis.

Yes. Admune Therapeutics was acquired by Novartis in October 2015.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available